Most buyers who arrive at a Neuralink listing come with a strong conviction: this company is doing something that has never been done before, and they want exposure early. That instinct is understandable. But conviction about a technology is not the same as a thesis about a secondary position. The two questions are related, but they are not the same question.

Before you bid, you need to answer four things clearly: What am I actually paying relative to known information? What structure am I buying — direct or SPV? What are the realistic exit scenarios, and over what timeframe? And what specific risks does this company carry that a typical late-stage private tech company does not?

What the secondary price actually reflects

Neuralink has not announced a public financing round with a disclosed valuation at a cadence comparable to, say, Anthropic or Stripe. Secondary marks — the prices at which trades clear in the open market — are therefore formed almost entirely from supply and demand among market participants rather than from a recent 409A anchor or a disclosed primary price. This matters because it means the bid-ask spread can be wide, and a clearing price in one month may look very different three months later after a single piece of clinical news.

A 409A valuation is an independent appraisal of a company's common stock fair market value, typically conducted to set option strike prices. In the absence of a fresh 409A or a disclosed primary round, secondary prices float on sentiment. Buyers should treat any quoted price as a market-clearing number, not an appraised value.

In thin secondary markets, the last cleared price tells you what one seller accepted and one buyer paid — not what the company is worth. Always ask how long ago that price cleared and whether the company's clinical or regulatory status has changed since.

Regulatory timeline as a pricing variable

Neuralink's business is subject to FDA oversight in a way that most private tech companies are not. The company is developing an implantable brain-computer interface — a Class III medical device, the most stringent category the FDA regulates. Approval timelines for Class III devices are measured in years, trial enrollment is controlled, and a single clinical adverse event can trigger a hold, a protocol amendment, or a public disclosure that moves secondary prices sharply.

This does not mean the regulatory path is blocked. Neuralink received Breakthrough Device Designation from the FDA, which provides a more interactive review process and can shorten timelines. But it does mean that the usual private tech framework — 'next primary round reprices the secondary mark' — applies here alongside a second repricing mechanism that most secondary buyers are not accustomed to modeling: clinical data releases and regulatory correspondence.

Buyers accustomed to software or fintech secondaries should adjust their framework. In those sectors, the major binary events are fundraising rounds and IPO filings. In med-tech and neuro-tech, binary events include IDE approvals, pivotal trial read-outs, and FDA panel meetings. Each of these can move a secondary mark more than a normal quarterly news cycle.

The cross-portfolio dynamic

Neuralink shares Elon Musk as a founder and controlling figure with SpaceX, xAI, and The Boring Company. This creates a correlation in market sentiment that does not exist for most secondary issuers. When news cycles around the founder are negative — regulatory scrutiny, executive departures at a sibling company, geopolitical controversy — secondary prices across all of these names can soften simultaneously, regardless of company-specific developments.

This is a risk that is genuinely hard to quantify, but it is real. Secondary market participants have observed this pattern repeatedly: a headline about one company in the portfolio creates bid withdrawal or price softening across names that share no operational connection. Buyers who already hold SpaceX or xAI exposure through secondary positions should think about this as a correlated risk factor, not a diversification.

Conversely, positive founder-driven sentiment can compress discounts faster than fundamentals would justify. Understanding which direction this dynamic is running at the moment you are bidding is part of the information work that belongs before an indication, not after.

Structure: direct transfer versus SPV

Most Neuralink secondary supply in the open market comes through special purpose vehicles (SPVs) rather than direct share transfers. An SPV is a limited liability company formed solely to hold an interest in a single issuer. When you buy an SPV interest, you are buying an economic interest in a fund that holds the underlying shares — you are not a direct shareholder of Neuralink. The distinction matters at exit.

Direct transfer
You become a stockholder on the Neuralink cap table (subject to company consent and ROFR). You receive proceeds directly at a liquidity event. Your cost basis is the price you paid on the secondary purchase date.
SPV interest
You own a membership interest in an LLC that holds Neuralink shares. At exit, the SPV manager distributes proceeds net of management fees and carried interest (typically 10–20% of profits above a hurdle). Your tax document is a Schedule K-1, not a 1099.
ROFR
Right of First Refusal — the company's contractual right to purchase shares before they transfer to a third-party buyer. ROFR exercise is more common in direct transfers than in SPV interest transfers, but SPV formation itself may require company consent depending on the charter documents.

For a company like Neuralink, where the cap table is tightly managed and the founder controls governance, direct transfers are more likely to encounter company consent friction. SPV structures allow the transfer of economic interest without a change in the cap table, which can reduce — though not eliminate — consent requirements. Buyers should confirm what consent mechanics apply to the specific lot before execution, not assume.

Liquidation preference and common stock position

Most secondary supply in any late-stage company comes from employees and early employees who hold common stock or options converted to common stock. Preferred stock — the class held by institutional investors in primary rounds — sits above common in a liquidation waterfall. This means that in an exit below the aggregate liquidation preference, common stockholders may receive little or nothing.

Neuralink is not a company with publicly disclosed capitalization details, so buyers cannot calculate the full liquidation stack from public documents. What buyers can do is ask the selling party for confirmation of share class, understand what the last disclosed primary round's liquidation multiple was, and model a range of exit scenarios including ones below the implied current valuation. The secondary market occasionally prices common stock as though preferred preferences do not exist — that is a mistake.

Paying a secondary price that implies a high exit valuation is only safe if you have modeled what common stock actually receives at that valuation after the liquidation stack is satisfied. Do the arithmetic before you bid.

Exit horizon and liquidity planning

There is no public filing or credible market signal indicating a Neuralink IPO timeline. The company's business model — a medical device requiring multi-year clinical validation and FDA approval — is structurally different from a software company that could file an S-1 on twelve to eighteen months' notice. Buyers should assume a five-to-ten year horizon as a baseline, not an exception.

Secondary re-sales of your position are possible, but the market for Neuralink interests is thinner than for names like Stripe or SpaceX. Thin float means that if you need liquidity, you may face a meaningful bid-ask spread or a wait for a matched buyer. This is a position that rewards patient capital — do not size it as though you can exit cleanly on short notice.

What to verify before you submit an indication

  • Share class and whether the lot is common stock, preferred, or an SPV interest referencing one of those.
  • The date of the most recent primary financing and the disclosed or estimated valuation at that round.
  • SPV fee and carry structure if applicable — management fee percentage, carried interest rate, and hurdle or preferred return, if any.
  • ROFR and company consent mechanics for this specific lot.
  • The seller's original acquisition date, which affects your assessment of how well-seasoned the holding is and what the seller's likely motivation is.
  • Whether any clinical holds, FDA correspondence, or material corporate changes have occurred since the lot was last marked.

Neuralink is one of 28 issuers available on the Limen Markets marketplace. Listings refresh hourly, and seller-side supply is confirmed at the time you submit an indication — so you are not competing against phantom inventory. Minimum position size is $25,000. If you are ready to review current availability, visit the marketplace. If you want to work through the SPV-versus-direct decision for this or any other issuer first, the buyer guide on that topic is a useful starting point.